pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

4,972 catalysts · 4,686 phase readout · 2,347 8k filing · 285 earnings · 201 pdufa · 172 phase 2 completion · 73 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 14 catalysts2026-07-23: 2 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: phase readout×type: earnings×type: recall×clear all
type
  • phase readout4,686
  • 8k filing2,347
  • earnings285
  • pdufa201
  • phase 2 completion172
  • phase 1 completion73
phase 2 initiation
62
  • phase 1 initiation40
  • phase 1 2 completion35
  • phase 0 trial completion23
  • therapy area

    no tagged catalysts yet

    Date TBD

    50
    ›RECRUITINGphase readoutNCT07244211: MAPT Protocol: Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP)

    Sponsor: University of Southern California. Phase: NA. Conditions: Femoral Neck Fractures

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04633811: Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone Formers

    Sponsor: University of Alabama at Birmingham. Phase: NA. Conditions: Kidney Stone

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07197944: Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

    Sponsor: Zealand Pharma. Phase: PHASE3. Conditions: Short Bowel Syndrome

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06894849: Text -Based Depression Screening Among Cancer Survivors

    Sponsor: Medical University of South Carolina. Phase: NA. Conditions: Cancer, Depression Secondary to Other Disease, Cancer Survivor

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06045338: Mind Body Intervention for Long COVID-19

    Sponsor: Beth Israel Deaconess Medical Center. Phase: NA. Conditions: Long COVID, Post-Acute Sequelae of COVID-19, COVID Long-Haul

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT07494058: A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter Conditions in Mexico

    Sponsor: Takeda. Phase: . Conditions: Lysosomal Disease

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT03253848: Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia

    Sponsor: ECOG-ACRIN Cancer Research Group. Phase: NA. Conditions: Acute Promyelocytic Leukemia With PML-RARA, t(15;17)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07394855: Mechanisms of Persistent Fatigue

    Sponsor: University Hospital, Akershus. Phase: . Conditions: Fatigue Post Viral

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07249658: Effects of Power and High-Intensity Gait Training for Functional Mobility an Ambulation in Chronic Stroke

    Sponsor: Riphah International University. Phase: NA. Conditions: Stroke

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06508658: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Sponsor: Genmab. Phase: PHASE3. Conditions: Diffuse Large B-Cell Lymphoma

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07257055: Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

    Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Phase 2 Study, MCL, BTKi, Rituximab, Glofitamab

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03315455: Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants

    Sponsor: Hoffmann-La Roche. Phase: PHASE3. Conditions: Hemophilia A

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06047548: A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

    Sponsor: Eli Lilly and Company. Phase: PHASE3. Conditions: Overweight, Obesity

    full page →ctgov ↗
    ›ENROLLING_BY_INVITATIONphase readoutNCT06285448: Feasibility of Lecanemab Registry and Clinical Outcome Measures

    Sponsor: HealthPartners Institute. Phase: . Conditions: Alzheimer Disease

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06507748: A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

    Sponsor: National Cancer Institute (NCI). Phase: NA. Conditions: Neurofibromatosis Type 1

    full page →ctgov ↗
    ›ENROLLING_BY_INVITATIONphase readoutNCT06720948: The ION Facet Screw System Ambispective Evaluation

    Sponsor: SurGenTec LLC. Phase: . Conditions: Intra-facet ION 3D Facet Screw System

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT04365855: The Olmsted NAFLD Epidemiology Study (TONES)

    Sponsor: Mayo Clinic. Phase: NA. Conditions: Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03787355: Clinical Evaluation of Vertical Inter-implant Papilla Height in Platform Matched Implants in Comparison to Morse Connection Abutments

    Sponsor: Cairo University. Phase: NA. Conditions: Interimplant Mucosa

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05821855: A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China

    Sponsor: AbbVie. Phase: PHASE4. Conditions: Open-angle Glaucoma, OAG

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT04184648: Comparison of Classification Standards of Bronchopulmonary Dysplasia (BPD) in Premature Infants

    Sponsor: Wang Jianhui. Phase: . Conditions: Bronchopulmonary Dysplasia

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07630948: Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer

    Sponsor: Institute of Oncology Ljubljana. Phase: PHASE4. Conditions: Breast Cancer, Adherence, Medication

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07595848: Integration of Wearable Sensor Devices Into a Single System to Predict the Onset of Sepsis

    Sponsor: Check Point R & D Ltd. Phase: NA. Conditions: Sepsis

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT07439055: Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A

    Sponsor: Chulalongkorn University. Phase: PHASE2. Conditions: Hemophilia A Patient

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07613255: Evaluating Metabolic Health in Individuals With Extreme Obesity

    Sponsor: Pennington Biomedical Research Center. Phase: . Conditions: BMI>40

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04567355: Migraine Manager (R01)

    Sponsor: Children's Hospital Medical Center, Cincinnati. Phase: PHASE2. Conditions: Migraine, Migraine Disorders

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06824155: HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

    Sponsor: Radiopharm Theranostics, Ltd. Phase: EARLY_PHASE1. Conditions: HER2 Gene Mutation, Advanced Solid Tumors

    full page →ctgov ↗
    ›TERMINATEDphase readoutNCT03630055: Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

    Sponsor: Ottawa Heart Institute Research Corporation. Phase: PHASE3. Conditions: Radial Artery Occlusion

    full page →ctgov ↗
    ›ENROLLING_BY_INVITATIONphase readoutNCT07137455: EDEN Intracardiac Electrogram Recording and Classifying System

    Sponsor: National Heart, Lung, and Blood Institute (NHLBI). Phase: NA. Conditions: Ventricular Arrhythmia

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05837455: NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

    Sponsor: Washington University School of Medicine. Phase: PHASE2. Conditions: Breast Cancer, Cancer of the Breast

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07436455: F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer

    Sponsor: Ankara University. Phase: NA. Conditions: Thyroid Cancer, Differentiated Thyroid Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07464938: New Tools and Predictive Markers in the Prognosis of Hypoxic-ischemic Encephalopathy Following Cardiac Arrest

    Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Phase: NA. Conditions: Cardiac Arrest (CA)

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07590648: Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia

    Sponsor: Hospital Universitari Vall d'Hebron Research Institute. Phase: PHASE4. Conditions: Febrile Neutropenia (FN), Pediatric Cancer, Hematologic Malignancies, Solid Tumors, Invasive Bacterial Infection

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT02896348: Assessment of a Physio-neuro Platform (SynPhNe) for Home-based Retraining of Hand Function in Stroke Survivors

    Sponsor: Spaulding Rehabilitation Hospital. Phase: NA. Conditions: Stroke, Hemiparesis

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06254248: Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma

    Sponsor: Assistance Publique - Hôpitaux de Paris. Phase: PHASE2. Conditions: Liver Transplant, Hepatocellular Carcinoma Recurrent, Systemic Treatment

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07369349: Artificial Int: Neurogenic Bowel Education in Spinal Cord Injury Patients

    Sponsor: Senem Duman. Phase: NA. Conditions: Spinal Cord Injury, Neurogenic Bowel Dysfunction

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05159349: Mental Health During the Whole Life Cycle of Community Patients With Schizophrenia

    Sponsor: Shanghai Mental Health Center. Phase: . Conditions: Schizophrenia

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07501338: Early Automated Insulin Delivery (AID) Pilot for Newly Diagnosed T1D

    Sponsor: Stanford University. Phase: NA. Conditions: Type 1 Diabetes

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04158258: A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

    Sponsor: Hoffmann-La Roche. Phase: . Conditions: Breast Cancer

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04806958: The PulsePoint Study

    Sponsor: Dr. Steven Brooks. Phase: NA. Conditions: Out-Of-Hospital Cardiac Arrest, Heart Arrest, Heart Diseases, Cardiovascular Diseases

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06234748: Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer

    Sponsor: University of Michigan Rogel Cancer Center. Phase: PHASE2. Conditions: Oropharynx Cancer, HPV-Related Carcinoma

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04391049: Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery

    Sponsor: NRG Oncology. Phase: PHASE1. Conditions: Advanced Esophageal Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma, Squamous Cell Cancer

    ›RECRUITINGphase readoutNCT06557148: A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer

    Sponsor: Memorial Sloan Kettering Cancer Center. Phase: . Conditions: Breast Cancer, Lobular Breast Carcinoma, Breast Carcinoma, Metastatic Breast Cancer, Metastatic Lobular Breast Carcinoma, Metastatic Breast Carcinoma

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06897748: A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils

    Sponsor: AstraZeneca. Phase: PHASE2. Conditions: Chronic Obstructive Pulmonary Disease (COPD)

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05856448: A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

    Sponsor: Lakefront Biotherapeutics NV. Phase: PHASE2. Conditions: Systemic Lupus Erythematosus

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04401748: Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

    Sponsor: AbbVie. Phase: PHASE3. Conditions: Myelodysplastic Syndrome (MDS)

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT07347548: A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male Participants

    Sponsor: Grünenthal GmbH. Phase: PHASE1. Conditions: Duchenne Muscular Dystrophy (DMD)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05791448: AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

    Sponsor: University of Southern California. Phase: PHASE1. Conditions: Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Refractory Malignant Solid Neoplasm, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07518043: A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

    Sponsor: Shanghai Henlius Biotech. Phase: PHASE1. Conditions: Esophageal and/or Cardia Cancer, Melanoma, Urothelial Carcinoma (UC)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07264426: Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

    Sponsor: argenx. Phase: . Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07501143: Effects of Physical Training in Patients With Advanced Heart Failure

    Sponsor: University of Nove de Julho. Phase: NA. Conditions: Insuficiência Cardíaca, Transplante Cardíaco, Exercício Físico

    full page →ctgov ↗
    ← prev
    page 58 of 100
    next →
    full page →ctgov ↗